Investigational drug · Phase 2
DNL151
Also called: BIIB122
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Parkinson Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
9
Any phase or sponsor naming "DNL151"
First trial start
2022
Apr 19, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DNL151", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson Disease
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "DNL151" as an intervention, largest first.
- A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80Pivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT05348785 · 650 participants · Start Apr 19, 2022 · Primary completion Mar 9, 2026
Drug: BIIB122; BIIB122-Matching Placebo · For: Parkinson Disease
Sites: Phoenix, Arizona; Sun City, Arizona; Los Angeles, California · 113 sites in all
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy VolunteersPivotal-lookingCompleted
Denali Therapeutics Inc.Industry
NCT04557800 · 186 participants · Start Nov 16, 2017 · Primary completion Feb 19, 2021
Drug: DNL151; Placebo · For: Healthy Volunteers
Sites: Leiden, Netherlands; Groningen, Netherlands
BiogenBiogen (BIIB)
NCT05229562 · 84 participants · Start Feb 17, 2022 · Primary completion Sep 7, 2022
Drug: BIIB122 · For: Healthy Volunteer
Sites: Anaheim, California
- Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)Active, not recruiting
Denali Therapeutics Inc.Industry
NCT06602193 · 50 participants (planned) · Start Oct 24, 2024 · Primary completion Mar 2027
Drug: BIIB122 225 mg · For: Parkinson Disease
Sites: Los Angeles, California; San Francisco, California; Boca Raton, Florida · 20 sites in all
BiogenBiogen (BIIB)
NCT04056689 · 36 participants · Start Jul 23, 2019 · Primary completion Dec 2, 2020
Drug: DNL151; Placebo · For: Parkinson's Disease
Sites: Orlando, Florida; Farmington Hills, Michigan; Leuven, Belgium · 8 sites in all
BiogenBiogen (BIIB)
NCT06264440 · 18 participants · Start Feb 12, 2024 · Primary completion Jun 18, 2024
Drug: BIIB122; Rabeprazole · For: Healthy Volunteer
Sites: Austin, Texas
BiogenBiogen (BIIB)
NCT05005338 · 8 participants · Start Jul 28, 2021 · Primary completion Sep 23, 2021
Drug: BIIB122 (DNL151); [14C] BIIB122 ([14C] DNL151) · For: Healthy Volunteers
Sites: Baltimore, Maryland
BiogenBiogen (BIIB)
NCT05418673 · 7 participants · Start Aug 26, 2022 · Primary completion Jul 27, 2023
Drug: BIIB122; BIIB122-Matching Placebo · For: Parkinson Disease
Sites: San Francisco, California; Aurora, Colorado; Englewood, Colorado · 27 sites in all
BiogenBiogen (BIIB)
NCT05119790 · 7 participants · Start Aug 27, 2021 · Primary completion Nov 5, 2021
Drug: [14C] BIIB122 ([14C] DNL151) · For: Healthy Volunteers
Sites: Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Therapeutics candidates and repurposing strategies to target parkinson's disease pathology: current evidence and future directions.
Dhanush Y, Nizamuddin ND, Neelima S, et al. · Metab Brain Dis 2026
- Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.
Cao R, Chen C, Wen J, et al. · Bioorg Chem 2023
- DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson's disease.
Müller T · Expert Opin Investig Drugs 2023
- LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.
Jennings D, Huntwork-Rodriguez S, Vissers MFJM, et al. · Mov Disord 2023
- Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present).
Ding X, Ren F · Expert Opin Ther Pat 2020
Also in development for Parkinson Disease
- RadotinibSupect, IY5511Phase 33 trials
Il-Yang Pharm. Co., Ltd. · Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory
- CVN424Phase 32 trials
Cerevance · Parkinson Disease, Parkinson's Disease
- BHV-8000Phase 31 trial
Biohaven Therapeutics Ltd. · Parkinson Disease
- Human Dopaminergic Progenitor CellsNouvNeu001Phase 23 trials
iRegene Therapeutics Co., Ltd. · Parkinson Disease, Parkinson Disease (PD)
- AB-1005Phase 22 trials
AskBio Inc · PARKINSON DISEASE (Disorder), Parkinson Disease
- HBI-002Phase 22 trials
Hillhurst Biopharmaceuticals, Inc. · Parkinson Disease, Anemia, Sickle Cell
- VutiglabridinHSG4112Phase 22 trials
Glaceum · Knee Osteoarthritis (Knee OA), Parkinson Disease
- AP-472Phase 21 trial
Appello Pharmaceuticals, Inc. · Parkinson Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.